Clinical Trial Update: Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of fulvestrant with and without entinostat in postmenopausal women with ER-positive advanced breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Entinostat (entinostat)
• Faslodex (fulvestrant)

Snippet

Sponsor: Syndax Pharmaceuticals | Conditions: Breast Cancer | Phase 2 | Status: WITHDRAWN